The New York-based AI biotech will use its AMICA-OS platform to analyze clinical immune data for BMS, aiming to inform patient stratification, biomarkers, and trial decisions.|  Read More  JPost.com – Business & Innovation | The Jerusalem Post  | Read More in Virtual Jerusalem.   Read More in Israel NOWlej.